Skip to main content
Funded Studies

William Dvořák Shrader, PhD

Chief Scientific Officer at AcureX Therapeutics Corporation

Location: San Carlos, CA United States

Dr. Shrader has 26 years of experience in the pharmaceutical industry. During the last 14 years, he has led teams that have advanced 3 drugs into the clinic for neurodegenerative diseases. These drugs have completed phase 2 clinical trials in Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), Friedriech’s ataxia (FA), Rett Syndrome, and Leigh Syndrome. For one of these drugs, Vatiquinone™, Dr. Shrader led a team which in 20 months and $5M, went from the discovery of that drug, to its first dose in a 4-year old girl with Leigh’s syndrome. Dr. Shrader has also successfully led a team for the development of clinical biomarkers for a phase 2 ALS trial, demonstrating target engagement.

Associated Grants

  • Codevelopment of Small-molecule Regulators of Miro1 for the Treatment of Parkinson’s Disease and a GLP Clinical Biomarker Assay


  • Pre-clinical Development of Compounds that Modulate Mitophagy through Regulation of the Mitochondrial GTPase Miro1


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.